John Overdeck’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-55,935
| Closed | -$46.1K | – | 3370 |
|
|
2025
Q1 | $46.1K | Sell |
55,935
-7,326
| -12% | -$7.06K | ﹤0.01% | 3051 |
|
|
2024
Q4 | $60.1K | Sell |
63,261
-13,357
| -17% | -$12.6K | ﹤0.01% | 3025 |
|
|
2024
Q3 | $76.6K | Sell |
76,618
-4,762
| -6% | -$5.27K | ﹤0.01% | 2924 |
|
|
2024
Q2 | $101K | Sell |
81,380
-50,940
| -38% | -$51.9K | ﹤0.01% | 2822 |
|
|
2024
Q1 | $172K | Sell |
132,320
-5,893
| -4% | -$6.72K | ﹤0.01% | 2746 |
|
|
2023
Q4 | $173K | Sell |
138,213
-61,925
| -31% | -$68.5K | ﹤0.01% | 2871 |
|
|
2023
Q3 | $260K | Sell |
200,138
-86,992
| -30% | -$141K | ﹤0.01% | 2543 |
|
|
2023
Q2 | $494K | Buy |
287,130
+125,488
| +78% | +$199K | ﹤0.01% | 2337 |
|
|
2023
Q1 | $236K | Sell |
161,642
-33,170
| -17% | -$63.6K | ﹤0.01% | 2507 |
|
|
2022
Q4 | $316K | Sell |
194,812
-46,844
| -19% | -$108K | ﹤0.01% | 2218 |
|
|
2022
Q3 | $810K | Sell |
241,656
-120,957
| -33% | -$546K | ﹤0.01% | 1555 |
|
|
2022
Q2 | $1.32M | Buy |
362,613
+292,706
| +419% | +$1.33M | ﹤0.01% | 1410 |
|
|
2022
Q1 | $505K | Buy |
69,907
+16,911
| +32% | +$144K | ﹤0.01% | 2007 |
|
|
2021
Q4 | $720K | Buy |
52,996
+32,901
| +164% | +$515K | ﹤0.01% | 2873 |
|
|
2021
Q3 | $421K | Buy |
+20,095
| New | +$432K | ﹤0.01% | 3395 |
|
John Overdeck's KRON Position: Q2 2025 in Review
John Overdeck sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 55,935 shares — an estimated $46.1K sold.
John Overdeck first reported a position in KRON in Q3 2021 and held it in 15 quarters. The position peaked at $1.32M in Q2 2022. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- John Overdeck reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- John Overdeck sold 55,935 Kronos Bio shares in Q2 2025, an estimated $46.1K.
- John Overdeck first reported a position in Kronos Bio in Q3 2021 and held it in 15 quarters.
- John Overdeck's Kronos Bio position peaked at $1.32M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Two Sigma Investments's 13F filing for Q2 2025, filed 14 Aug 2025.